How to appeal a Kaiser Permanente spinal muscular atrophy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Kaiser Permanente-specific note: Integrated delivery system — care + insurance coordinated. California DMHC oversight is unique. CA IMR (Independent Medical Review) is a powerful external review track for Kaiser denials.

What Kaiser Permanente's policy requires for spinal muscular atrophy

Cited policy: Kaiser Posterior Spinal Fusion / Growing Rod Construct for Neuromuscular Scoliosis

Cobb angle >=50° in skeletally immature OR progressive curve >=10°/yr. Underlying SMA Type 2 or 3 with documented loss of sitting balance, pulmonary compromise from curve, or skin breakdown. Growing-rod constructs (VEPTR, MAGEC) preferred in patients <10 yr to preserve thoracic growth. Pediatric orthopedic surgery + neuromuscular specialist co-management. Pre-op pulmonary + cardiac + nutrition optimization.

How Kaiser Permanente denies spinal muscular atrophy — and how to counter it

Where Kaiser Permanente pushes back: 1) Curve not severe enough; 2) Bracing trial first; 3) Patient not ambulatory — questioned medical benefit.

Counter-arguments that hold up: SMA Standards of Care 2018 Part 1 (Mercuri Finkel Muntoni Neuromuscul Disord 2018;28(2):103-115) — orthopedic consensus endorses surgical correction for neuromuscular scoliosis Cobb >=50° in non-ambulatory Type 2 to preserve sitting balance, pulmonary function, and pelvic obliquity. Bracing in neuromuscular scoliosis is palliative not corrective and does NOT halt progression (Mullender 2008; Fujak Form 2013). Even non-ambulatory patients benefit from sitting-tolerance + reduced pulmonary restriction + skin care. Growing-rod constructs (VEPTR/MAGEC) preserve thoracic growth and lung development per Skaggs Akbarnia 2014. Submit curve trajectory, pulmonary function trend, sitting tolerance, and pediatric orthopedic letter.

What Kaiser Permanente typically denies for spinal muscular atrophy

Across Kaiser Permanente's commercial and Medicare books, denials cluster around a small number of patterns. For spinal muscular atrophy, expect:

• Out-of-network non-emergency denials
• Specialty referrals delayed
• Mental health access (DMHC complaints common)

Treatments most often denied in this category

These are the spinal muscular atrophy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Spinraza (nusinersen)
• Evrysdi (risdiplam)
• Zolgensma (onasemnogene)
• Combination/sequential
• Switching therapy
• BiPAP / NIV

How to submit the appeal to Kaiser Permanente

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Kaiser Permanente cited in the denial.
3. File the appeal through Kaiser Permanente's portal (members: https://my.kaiserpermanente.org ; providers: https://providers.kaiserpermanente.org). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In California, file through DMHC for HMOs or CDI for PPOs.

Clinician or prior-auth team handling this on the practice side? See Kaiser Permanente's prior-authorization criteria by drug: Kaiser Permanente PA criteria on ApprovalHelp.